Other Clinical Trials. Nothing in this Agreement shall preclude either Party from conducting any other clinical trials as it may determine in its discretion, so long as it does not use or rely on the Confidential Information that is solely owned by the other Party in doing so.
Other Clinical Trials. XXXXX shall continue to conduct the [****************] clinical trials, even after the regulatory sponsorship for such clinical trials transfers to PFIZER in accordance with Section 1.2, until such trials are completed. For clarity, XXXXX shall continue to conduct such clinical trials pursuant to its own internal processes and procedures (consistent with past practices), except as may be reasonably requested otherwise by the Pfizer Program Leader.
Other Clinical Trials. Except for the Combined Therapy Trials, each clinical trial for the Nektar Compound and the CPI Compound and the BioXcel Compound, alone or in combination with other pharmaceutical agents, is independently conducted and shall not be subject to this Agreement (but without limiting each Party’s obligation to share relevant safety information as provided in Section 2.1(c), Section 2.1(d) and Section 2.2). The Nektar Compound provided to BioXcel under this Agreement shall not be used for such other clinical trials. Nothing in this CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WHERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Agreement shall preclude either Party from conducting any such other clinical trials as it may determine in its discretion, so long as it does not use or rely on the Confidential Information of the other Party in doing so.
Other Clinical Trials. As long as the Co-Promotion Agreement has not been terminated, any additional clinical trial for the Licensed Product in the Field of Use in the Co-Promotion Region (including Phase 3b trials and Phase 4 trials that the JMC (defined below) desires to conduct), other than those set forth above, shall, upon the mutual agreement by the Parties, be documented in a joint development plan (including protocol, timeline and budget) as a modification to the JDP, and shall be conducted by the Parties in accordance with the JDP. If Spectrum elects not to conduct such clinical trials or not to fund such clinical trials upfront, Allergan may still conduct such clinical trials, and the Development Costs incurred in such clinical trials shall be split evenly. At Spectrum’s request, Allergan shall pay all of the Development Costs for such performance and shall receive a credit for such payments for Spectrum’s share of such costs from royalties and milestone payments due hereunder. Allergan shall be the sponsor of all such clinical trials that Spectrum elects not to conduct. Any additional clinical trials outside the Co-Promotion Region shall be conducted and paid for by Allergan.
Other Clinical Trials. Defiante may perform other pre-clinical and clinical trials in the Territory within the Field of Use with respect to the Finished Products.
Other Clinical Trials. Except for the Combined Therapy Trials, each clinical trial for the BMS Compound(s) and the Exelixis Compound, alone or in combination with other pharmaceutical agents, is independently conducted and shall not be subject to this Agreement (but without limiting each Party’s obligation to share relevant safety information as provided in this Agreement, the Quality Agreement or the Pharmacovigilance Agreement). BMS Compound(s) provided to Exelixis and Exelixis Compound provided to BMS under this Agreement shall not be used for such other clinical trials. Nothing in this Agreement shall preclude a Party from conducting any such other clinical trials as it may determine in its discretion, so long as it does not use or rely on the Confidential Information of the other Party in doing so. 5.4
Other Clinical Trials. At Licensee’s request, Duality shall perform any other Clinical Trial of an Original ADC Licensed Product (other than the Planned Trials or Original ADC Added Trials) or of an Next Generation ADC Licensed Product (other than the Next Generation Added Trials). The Parties shall discuss (through the JSC) Licensee’s funding [***].
Other Clinical Trials. Except for the Combined Therapy Trials, each clinical trial for the BMS Compound and the Nektar Compound, alone or in combination with other pharmaceutical agents, is independently conducted and shall not be subject to this Agreement Clinical Trial Collaboration Agreement_Nektar_BMS_September 2016 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 (but without limiting each Party’s obligation to share relevant safety information as provided in Section 2.1(c), Section 2.1(d) and Section 2.2). The BMS Compound provided to Nektar under this Agreement shall not be used for such other clinical trials. The Nektar Compound provided to BMS under this Agreement shall not be used for such other clinical trials. Except as provided in Section 3.5 and Exhibit C, nothing in this Agreement shall preclude either Party from conducting any such other clinical trials as it may determine in its discretion, so long as it does not use or rely on the Confidential Information of the other Party in doing so.
Other Clinical Trials. Except for each Collaboration Trial conducted under this Agreement, any other clinical trial for the 435 Compound, 055 Compound and the Idenix Compound is independently conducted and shall not be subject to this Agreement.
Other Clinical Trials. Sigma-Tau may perform other clinical trials in the Territory with respect to the Licensed Product upon the mutual written agreement of Sigma-Tau and SPIL, which approval shall not be unreasonably withheld or delayed.
